Title |
Use of palliative sedation for intractable symptoms in the palliative care unit of a comprehensive cancer center
|
---|---|
Published in |
Supportive Care in Cancer, May 2008
|
DOI | 10.1007/s00520-008-0459-4 |
Pubmed ID | |
Authors |
Ahmed Elsayem, Eardie Curry III, Jeanette Boohene, Mark F. Munsell, Bianca Calderon, Frank Hung, Eduardo Bruera |
Abstract |
There is wide variation in the frequency of reported use of palliative sedation (PS) to control intractable and refractory symptoms in terminally ill patients. The aim of this study was to determine the frequency and outcomes of PS use and examine patterns of practice after establishment of a policy for the administration of midazolam for PS in our palliative care unit (PCU). |
X Demographics
The data shown below were collected from the profiles of 114 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 22 | 19% |
United States | 17 | 15% |
United Kingdom | 8 | 7% |
Italy | 4 | 4% |
Brazil | 3 | 3% |
Venezuela, Bolivarian Republic of | 3 | 3% |
Netherlands | 3 | 3% |
Mexico | 3 | 3% |
Canada | 2 | 2% |
Other | 10 | 9% |
Unknown | 39 | 34% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 81 | 71% |
Practitioners (doctors, other healthcare professionals) | 17 | 15% |
Scientists | 11 | 10% |
Science communicators (journalists, bloggers, editors) | 4 | 4% |
Unknown | 1 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Portugal | 1 | 1% |
Austria | 1 | 1% |
United Kingdom | 1 | 1% |
Canada | 1 | 1% |
Spain | 1 | 1% |
Unknown | 75 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 17 | 21% |
Researcher | 10 | 13% |
Student > Bachelor | 7 | 9% |
Student > Postgraduate | 6 | 8% |
Student > Doctoral Student | 5 | 6% |
Other | 18 | 23% |
Unknown | 17 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 44 | 55% |
Nursing and Health Professions | 8 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
Agricultural and Biological Sciences | 3 | 4% |
Psychology | 2 | 3% |
Other | 3 | 4% |
Unknown | 17 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 82. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 April 2020.
All research outputs
#529,377
of 25,754,670 outputs
Outputs from Supportive Care in Cancer
#24
of 5,122 outputs
Outputs of similar age
#905
of 88,089 outputs
Outputs of similar age from Supportive Care in Cancer
#1
of 12 outputs
Altmetric has tracked 25,754,670 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,122 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 88,089 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.